JASCAYD
Oct 10, 2025
Boehringer Ingelheim’s JASCAYD Brings Hope Back to IPF Patients After a Decade of Waiting
Over a decade after launching one of the first treatments for idiopathic pulmonary fibrosis, Boehringer Ingelheim is rejuvenating its presence in the rare lung disease arena with a newly approved therapy. On October 7, the FDA approved JASCAYD, marking the first new IPF treatment in over ten years. The approval fol...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
